Potential cellular intravesical therapy for non-muscle invasive bladder cancer: Nectin-4 targeted CAR-T cell therapy
Authors:
- Emre AltıntaşEAEmre Altıntaş
- Ali ŞahinAŞAli Şahin
- Huseyn BabayevHBHuseyn Babayev
- Murat GülMGMurat Gül
- 21 April 2024
- journal article
- research article
- Published by Elsevier in Medical Hypotheses
- Vol. 187
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- FAP-targeted CAR T-cell therapy: A promising approach for the treatment of Peyronie’s diseaseMedical Hypotheses, 2023
- Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancerVirchows Archiv, 2022
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)European Urology, 2022
- Bladder CancerJAMA, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor RecurrenceJAMA, 2018
- Chimeric Antigen Receptors: A Cell and Gene Therapy PerspectiveMolecular Therapy, 2017
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, 2016
- Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and OutcomesEuropean Urology, 2016
- Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapyCancer Immunology, Immunotherapy, 1994